MeiraGTx Holdings

MGTX · NASDAQ

$9.97+$0.52 (+5.50%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $9.45

MGTX analyst rating

BuyConsensus of 8 analysts over the last 12 months. 88% rate it a buy.

Strong buy1
Buy6
Hold1
Underperform0
Sell0

12-month price target · 10 analysts

Average $28.31 (+183.9% upside)

Low: $16.16
Now: $9.97
High: $52.50

Upgrades and downgrades

The latest rating actions, newest first

MGTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Goldman Sachs	Sep 24, 2026	Initiates	Neutral	$16.00	42%
RBC Capital	Aug 14, 2026	Maintains	Outperform	$26.00 → $27.00	44%
RBC Capital	Jul 8, 2026	Maintains	Outperform	$25.00 → $26.00	44%
HC Wainwright & Co.	Jul 8, 2026	Maintains	Buy	$20.00	32%
RBC Capital	May 15, 2026	Maintains	Outperform	$24.00 → $25.00	44%
Piper Sandler	Apr 22, 2026	Maintains	Overweight	$26.00 → $30.00	55%
RBC Capital	Apr 17, 2026	Maintains	Outperform	$16.00 → $24.00	44%
Evercore ISI Group	Apr 1, 2026	Maintains	Outperform	$20.00 → $18.00	42%
Piper Sandler	Mar 27, 2026	Maintains	Overweight	$30.00 → $26.00	55%
B of A Securities	Mar 27, 2026	Maintains	Buy	$14.00 → $16.00	60%

The case for and against

Updated Oct 14, 2026

Bull case

MeiraGTx Holdings is supported by a strengthened, largely non-dilutive funding profile, including a $400M Oberland Capital package and a $200M upfront Parkinson’s partnership, which together help extend runway, repay the $75m Perceptive debt, and fund late-stage execution without an immediate equity overhang. Its outlook is further improved by multiple clinical and regulatory catalysts: bota-vec in XLRP is now anticipated to file the BLA in 2026 with a 2027 commercial launch planned, while xerostomia’s pivotal study is fully enrolled with a 2Q27 readout and possible late-’27 approval. The company also owns differentiated assets with meaningful unmet need, including a Phase III-ready Parkinson’s program, ultra-rare retinal disease programs, and end-to-end manufacturing capabilities that can support IND-to-commercial supply.

Bear case

MeiraGTx Holdings is a clinical-stage genetic medicines company whose valuation rests on uncertain pipeline execution rather than recurring revenue, making outcomes highly speculative and volatile. The negative outlook is driven by elevated risks of clinical trial delays, regulatory uncertainty, efficacy or safety setbacks, IP challenges, and competitive pressure, all of which are heightened by the company’s non-revenue-generating status and dependence on positive data from programs such as AAV-AQP1, bota-vec, and AAV-AIPL1. Even with an estimated enterprise value of about $2.1B and roughly $309M in cash, cash equivalents, and investments at end-2Q27, the threat of long-term dilution and failure to translate development assets into approved products supports a cautious stance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.